Insider

BeOne Medicines boosts third-quarter revenue from key drugs

BeOne Medicines Ltd. reported third-quarter 2026 financial results, with global sales of BRUKINSA reaching $1.4 billion and free cash flow of $474 million. For shareholders, this signals strengthened financials driven by core oncology product sales, allowing the company to revise its annual guidance.

Verified against 3 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
white and red exit sign
Photo by Cory Mogk on Unsplash
$1.4 billion
BRUKINSA global sales
$474 million
Free cash flow
$243 million
TEVIMBRA global sales

Key points

  • For the quarter ended September 30, 2026, global BRUKINSA sales rose 34% to $1.4 billion, with $1.0 billion from the U.S. market.
  • The company decided to stop promoting POBEVCY, leading to a $22 million impairment charge on intangible assets.

Quarterly financial results

For the quarter ended September 30, 2026, global BRUKINSA sales rose 34% to $1.4 billion, with $1.0 billion from the U.S. market. TEVIMBRA sales reached $243 million, a 28% increase. Net income for the third quarter hit $385 million, and free cash flow was $474 million.

Key financial indicators (Q3 2026)

BRUKINSA, global sales
$1.4 billion
TEVIMBRA, global sales
$243 million
Net income (GAAP)
$385 million
Free cash flow
$474 million
Data from the original sources listed alongside.

Revenue by quarter, $B

1.1Q4 '24*-7%1.1Q1 '251%1.3Q2 '256.7%1.4Q3 '2511.5%1.5Q4 '25*12.4%1.5Q1 '2616.5%1.7Q2 '2619.1%1.9Q3 '2622.2%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

Portfolio adjustments and management decisions

The company decided to stop promoting POBEVCY, leading to a $22 million impairment charge on intangible assets. This move aims to optimize expenses and refocus strategic priorities.

On October 27, 2026, director Wang Xiaodong sold 31,028 company shares. The transaction followed a pre-approved Rule 10b5-1 trading plan—a preset selling schedule executives set up in advance that allows insiders to sell shares without affecting the confidentiality of current strategic information.

What to watch

Shareholders should look to the annual report for final 2026 revenue and operating income figures. That report will evaluate whether the company met the updated financial guidance issued after the third quarter.

Original sources

  1. 8-K filing, November 5, 2026November 5, 2026SHA-256 of our archived copy 38d1a23b8f46…
  2. 8-K EX-99.1 filing, November 5, 2026November 5, 2026SHA-256 of our archived copy a6323c2ba025…
  3. 4 filing, October 29, 2026October 29, 2026SHA-256 of our archived copy 28ebca90956e…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards